Kyowa Kirin Competitors and Similar CompaniesClear all
Kyowa Kirin's competitors and similar companies include Takeda, CureVac, Biocon and Shanghai Junshi Biosciences.
 Kyowa Kirin Kyowa Kirin (formerly Kyowa Hakko Kirin) is a pharmaceutical company focused on the areas of oncology, nephrology, immunology, and the central nervous system. |  Takeda Takeda Pharmaceutical (武田薬品工業株式会社) is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products. |  Shanghai Junshi Biosciences Shanghai Junshi Biosciences (上海君實生物醫藥科技) is a biopharmaceutical company focused on the treatment of cancer, autoimmune, and metabolic diseases. | |||
Founding Date | Founding Date 2008 | Founding Date 1781 | Founding Date 2000 | Founding Date 1978 | Founding Date 2012 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Tübingen, DE HQ Ottignies Louvain La Neuve, BE Wiesbaden, DE Amsterdam, NL Basel, CH Boston, US | Locations Bengaluru, IN HQ Bengaluru, IN Nanakramguda, IN Dublin, IE Kuala Lumpur, MY Puchong, MY Delémont, CH see more | Locations Shanghai, CN HQ | ||
Employees | Employees 5,669 | Employees 47,4554% decrease | Employees 82517% decrease | Employees 16,5612% increase | Employees 2,578 |
Valuation ($) | Valuation ($) 8.8 b | Valuation ($) 43.7 b | Valuation ($) 648.3 m | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) ¥496.8b (FY, 2025) | Revenue (est.) ¥4.6t (FY, 2025) | Revenue (est.) €535.2m (FY, 2024) | Revenue (est.) ₹167.8b (FY, 2026) | Revenue (est.) ¥2.4b (FY, 2025) |
Cost of goods | Cost of goods ¥114.3b (FY, 2025) | Cost of goods ¥818.8b (FY, 2025) | Cost of goods €9.7m (FY, 2024) | Cost of goods ₹56.9b (FY, 2026) | Cost of goods ¥466.5m (FY, 2025) |
Gross profit | Gross profit ¥383.4b (FY, 2025) | Gross profit ¥3.8t (FY, 2025) | Gross profit €534.4m (FY, 2024) | Gross profit ₹115.8b (FY, 2026) | Gross profit ¥2b (FY, 2025) |
Net income | Net income ¥67b (FY, 2025) | Net income ¥108.1b (FY, 2025) | Net income €162.2m (FY, 2024) | Net income ₹3.7b (FY, 2026) | Net income (¥1b) (FY, 2025) |
Operating ⚠ | |||||
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products 2 (May, 2025) | Phase I Trials Products 3 (May, 2020) | Phase I Trials Products N/A | Phase I Trials Products N/A |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 57.8m | Total funding raised $ 1.1b | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Takeda
HQ
Tokyo, JP
Employees
47,455↓ 4% decrease
Takeda Pharmaceutical (武田薬品工業株式会社) is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products.
View company
CureVac
HQ
Tübingen, DE
Employees
825↓ 17% decrease
CureVac is a biotechnology company offering messenger RNA (mRNA) technology.
View company
Biocon
HQ
Bengaluru, IN
Employees
16,561↑ 2% increase
Biocon is a company that develops and manufactures biopharmaceutical products.
View companyShanghai Junshi Biosciences
HQ
Shanghai, CN
Employees
2,578
Shanghai Junshi Biosciences (上海君實生物醫藥科技) is a biopharmaceutical company focused on the treatment of cancer, autoimmune, and metabolic diseases.
View company